Literature DB >> 21651459

Opioid modulators for alcohol dependence.

Thomas Hillemacher1, Annemarie Heberlein, Marc An Muschler, Stefan Bleich, Helge Frieling.   

Abstract

INTRODUCTION: Studies have shown that opioid antagonists like naltrexone are efficient in reducing heavy drinking. The neurobiological mechanism by which opioid modulators affect drinking behavior is based on the strong connection between the endogenous opioid system, the dopamine system and the influence of the CNS stress response. AREAS COVERED: This review provides an overview of the pathophysiological role of the opioid system in alcohol dependence and the neurobiological mechanisms of possible pharmacological interventions. An extensive Medline and Internet research was performed to retrieve information on existing and currently investigated opioid modulators. The findings were assessed critically and interpreted with regard to an individualized therapy for alcohol dependence. EXPERT OPINION: The opioid system is of crucial importance in the genesis and maintenance of alcohol dependence. Naltrexone- and to a lesser extent nalmefene- is an agent that modulates opioidergic transmission in the CNS and it shows a limited but well-studied efficacy in treating alcohol dependence. Several agents (LY2196044, ALKS-29, ALKS-33) that are currently undergoing Phase II and Phase III studies are of interest but first their efficacy must be proved in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21651459     DOI: 10.1517/13543784.2011.592139

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  6 in total

1.  Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependence.

Authors:  Daniel D Langleben; Elliot L Busch; Charles P O'Brien; Igor Elman
Journal:  Psychopharmacology (Berl)       Date:  2011-09-30       Impact factor: 4.530

Review 2.  [Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].

Authors:  M Gahr; M A Kölle; C Schönfeldt-Lecuona
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

3.  Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity.

Authors:  Elizabeth Murray; Sietske Brouwer; Rob McCutcheon; Catherine J Harmer; Philip J Cowen; Ciara McCabe
Journal:  Psychopharmacology (Berl)       Date:  2014-04-25       Impact factor: 4.530

4.  Pharmacological management of binge eating disorder: current and emerging treatment options.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Anne M O'Melia
Journal:  Ther Clin Risk Manag       Date:  2012-05-08       Impact factor: 2.423

Review 5.  Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.

Authors:  Pascal Valentin Fischler; Michael Soyka; Erich Seifritz; Jochen Mutschler
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

6.  Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues.

Authors:  G-J Wang; D Tomasi; N D Volkow; R Wang; F Telang; E C Caparelli; E Dunayevich
Journal:  Int J Obes (Lond)       Date:  2013-08-08       Impact factor: 5.095

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.